Baolingbao Biology Co.,Ltd. (SHE:002286)

Market Cap	3.78B +29.5%
Revenue (ttm)	2.81B +11.0%
Net Income	154.40M +11.6%
EPS	0.41 +8.6%
Shares Out	380.57M
PE Ratio	24.06
Forward PE	n/a
Dividend	0.12 (1.16%)
Ex-Dividend Date	Jul 3, 2025

Volume	14,424,500
Average Volume	9,099,677
Open	10.06
Previous Close	10.38
Day's Range	9.86 - 10.39
52-Week Range	8.68 - 13.40
Beta	0.57
RSI	44.68
Earnings Date	Apr 25, 2026

About Baolingbao Biology

Baolingbao Biology Co.,Ltd. researches and develops, manufactures, and sells a range of functional sugars in China. The company offers prebiotics, such as isomaltooligosaccharides, galactooligosaccharides, fructooligosaccharides, bagasse trisaccharides, and xylooligosaccharides; sugar alcohols and new sugar source products, including erythritol, trehalose, crystalline fructose, alodonose, and maltose; dietary fiber products comprising polydextrose and resistant dextrin; modified, waxy maize, and corn starch products; starch sugar products, incl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 1,395
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002286

Financial Performance

In 2025, Baolingbao Biology's revenue was 2.75 billion, an increase of 14.54% compared to the previous year's 2.40 billion. Earnings were 150.63 million, an increase of 35.50%.